NVAX

Novavax Inc

NVAX, USA

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

https://www.novavax.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
NVAX
stock
NVAX

NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback? ts2.tech

Read more →
NVAX
stock
NVAX

What Market Correlation Trends Mean for JSW Holdings Limited’s Performance - Technology Stock Trends & Free Proven Portfolio Growth Strategies earlytimes.in

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$12.6667

Analyst Picks

Strong Buy

3

Buy

1

Hold

2

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

3.33

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

-6.80

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

129.17 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-17.15 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

150.17 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 68.32% of the total shares of Novavax Inc

1.

Vanguard Group Inc

(9.5019%)

since

2025/06/30

2.

BlackRock Inc

(7.8457%)

since

2025/06/30

3.

Shah Capital Management

(7.0876%)

since

2025/06/30

4.

Sanofi

(4.2362%)

since

2025/06/30

5.

State Street Corp

(4.2016%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(2.956%)

since

2025/07/31

7.

D. E. Shaw & Co LP

(2.4264%)

since

2025/06/30

8.

Coatue Management LLC

(2.3624%)

since

2025/06/30

9.

Geode Capital Management, LLC

(2.3201%)

since

2025/06/30

10.

Vanguard Small Cap Index

(2.2985%)

since

2025/07/31

11.

iShares Russell 2000 ETF

(2.2319%)

since

2025/08/31

12.

Bank of America Corp

(1.9304%)

since

2025/06/30

13.

SPDR® S&P Biotech ETF

(1.9054%)

since

2025/08/31

14.

UBS Group AG

(1.3891%)

since

2025/06/30

15.

Millennium Management LLC

(1.245%)

since

2025/06/30

16.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0731%)

since

2025/07/31

17.

Fidelity Small Cap Index

(0.9277%)

since

2025/06/30

18.

TSP Capital Management Group/LLC

(0.8614%)

since

2025/06/30

19.

Northern Trust Corp

(0.8201%)

since

2025/06/30

20.

Charles Schwab Investment Management Inc

(0.8115%)

since

2025/06/30

21.

Morgan Stanley - Brokerage Accounts

(0.7627%)

since

2025/06/30

22.

Vanguard Small Cap Value Index Inv

(0.7419%)

since

2025/07/31

23.

iShares Russell 2000 Growth ETF

(0.6714%)

since

2025/08/31

24.

Royal Bank of Canada

(0.6632%)

since

2025/06/30

25.

Vanguard Small Cap Growth Index Inv

(0.6451%)

since

2025/07/31

26.

Deep Track Capital, LP

(0.6148%)

since

2025/06/30

27.

Jane Street Group LLC

(0.6144%)

since

2025/06/30

28.

Susquehanna International Group, LLP

(0.5736%)

since

2025/06/30

29.

SG Americas Securities, LLC

(0.5558%)

since

2025/06/30

30.

iShares Biotechnology ETF

(0.544%)

since

2025/08/31

31.

Fidelity Extended Market Index

(0.5407%)

since

2025/07/31

32.

Jupiter Merian Glb Eq AbsRet I USD Acc

(0.5015%)

since

2025/06/30

33.

Schwab US Small-Cap ETF™

(0.4702%)

since

2025/08/30

34.

Vanguard Russell 2000 ETF

(0.4393%)

since

2025/07/31

35.

State St Russell Sm Cap® Indx SL Cl I

(0.325%)

since

2025/08/31

36.

Vanguard Health Care ETF

(0.2756%)

since

2025/07/31

37.

PIMCO RAE US Small Instl

(0.242%)

since

2025/06/30

38.

PIMCO RAE US Small

(0.242%)

since

2025/06/30

39.

Schwab Small Cap Index

(0.2351%)

since

2025/07/31

40.

iShares Genomics Immnlgy & Hlthcr ETF

(0.2263%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.4206

Latest Release

Date

2025-09-30

EPS Actual

-1.25

EPS Estimate

-0.5427

EPS Difference

-0.7073

Surprise Percent

-130.3298%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(8.8)
GARP
Fair GARP(4)
Growth
Moderate Growth(4.5)
Momentum
Strong Momentum(7)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Moderate Quality(4.5)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.